Mounjaro®
Starting from £179.99/mo
Start journey Learn moreXanax (alprazolam) and Mounjaro (tirzepatide) are not known to cause a direct pharmacological interaction, but taking them together still raises real questions worth working through with a prescriber. Mounjaro slows gastric emptying, which can alter how quickly oral medicines are absorbed — and that matters for any tablet you rely on. These are both prescription-only medicines requiring clinical assessment before use, so any decision about taking them together belongs with your healthcare team. Here is what the current evidence actually shows, and what to flag at your next appointment.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Mounjaro works partly by slowing the rate at which food and liquids leave your stomach. That same mechanism, gastric emptying delay, can push back the point at which an oral tablet reaches your small intestine and enters your bloodstream. For some medicines this is clinically irrelevant. For others it matters quite a bit.
Alprazolam is absorbed relatively quickly under normal circumstances, with peak plasma levels typically reached within one to two hours of swallowing a tablet. If gastric emptying is slower than usual, that peak may arrive later or be flatter. In most people this probably makes little practical difference to a stable, long-term prescription. But if you take alprazolam as and when you need it (say, before a stressful event or at a specific time) a delayed onset could feel as though the medicine is not working, which sometimes prompts people to take more.
The NHS medicines page for tirzepatide notes that Mounjaro can affect the absorption of oral medicines generally, and advises letting prescribers know about everything you take. That is the right starting point. The Mounjaro SmPC on the eMC reinforces this for any co-prescribed oral medication.
Worth noting: the gastric-emptying effect tends to be most pronounced in the early weeks of treatment and after each dose increase, so if you have been stable on both medicines for a long time, the practical impact may be smaller than it would be for someone just starting Mounjaro.
Mounjaro's most common side effects are gastrointestinal (nausea, loose stools, indigestion) but dizziness and fatigue also appear on the list, particularly in the first few weeks. Alprazolam, as a benzodiazepine, directly depresses the central nervous system: sedation, slowed reaction time, and dizziness are its expected effects at therapeutic doses.
There is no published evidence of a dangerous interaction specifically between tirzepatide and alprazolam. The two medicines work through completely different pathways, one acts on GIP and GLP-1 receptors in your gut and brain, the other on GABA receptors in your central nervous system. They do not compete for the same enzymes or receptors in a way that would produce a dramatic combined effect.
That said, if you are already experiencing Mounjaro-related dizziness or fatigue, adding or increasing a sedating medicine can compound those symptoms. This is less a pharmacological interaction and more an additive burden. Our clinical team hears this concern fairly regularly, particularly from people who were already managing anxiety before starting weight-loss treatment.
If you notice unusual drowsiness, confusion or difficulty balancing after starting Mounjaro, let both your prescribers know promptly. Do not adjust either dose on your own.
The practical answer is: everything. When a clinician reviews your suitability for Mounjaro, a complete medicines list (including any controlled drugs, PRN (as-needed) medicines, and supplements) is essential. This applies whether you are speaking to your GP, a specialist, or a clinician at an online pharmacy.
For people managing anxiety alongside obesity, the interaction question sometimes becomes the one that stalls treatment unnecessarily. Anxiety and weight are often linked, and tirzepatide has a reasonable evidence base for improving quality of life alongside weight reduction, so the clinical picture is rarely black-and-white.
Specific things worth raising: how often you take alprazolam and at what dose; whether you take it at a fixed time or as needed; whether anxiety itself might influence your weight or eating patterns; and whether your current benzodiazepine prescription is regularly reviewed. Some people find that changes in appetite and eating habits during Mounjaro treatment also affect their anxiety, so keeping both prescribers in the loop matters throughout, not just at the start. If you are curious about how Mounjaro interacts with other medicines more broadly, our guide to taking other GLP-1 medicines alongside Mounjaro covers some of the same absorption principles in a different context.
One practical note: if you are planning to start Mounjaro around a period of disrupted routine (a holiday, a week of shift work, the run-up to a stressful deadline) that is worth mentioning too. Anxiety tends to spike at those times, and your alprazolam use may change, which could interact with any gastric-emptying shift at the start of treatment. It is also worth knowing that other concurrent health situations can raise similar questions, and our page on whether you can take Mounjaro while you have flu illustrates how temporary changes to your routine or health can affect your treatment plan in ways that are worth discussing with a prescriber.
Questions about Mounjaro and Xanax together are common among people who already take a prescribed benzodiazepine and are exploring weight-loss treatment for the first time. If your GP is not yet prescribing Mounjaro in their practice, a private consultation is often the most practical route, and a thorough medicines review should be part of that process regardless of provider.
For context on what private Mounjaro treatment costs and what reputable services include, our honest breakdown of Mounjaro pricing in the UK covers what legitimate prescriptions should involve, which matters if you are managing multiple medicines and need consistent clinical oversight. A prescriber who is not asking about your full medicines list is a concern. Every consultation at nume is reviewed personally by a GPhC-registered Independent Prescriber (a real clinician reads your answers, not an automated system) and your existing prescriptions are part of that picture, including hormonal treatments such as HRT, which is why we have a dedicated page covering how Mounjaro and HRT can be used together for anyone who needs that guidance. You can find more detail on how our team approaches complex cases on our frequently asked questions page.
If you are weighing up how Mounjaro fits into your broader health picture, including other treatments you already take, starting a free consultation is the most direct route to a proper clinical answer.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.